Molly Henderson - 30 Nov 2021 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Financial Officer
Signature
/s/ Jason Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
30 Nov 2021
Net transactions value
-$31,122
Form type
4
Filing time
02 Dec 2021, 12:15:17 UTC
Previous filing
08 Jun 2021
Next filing
02 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +5,000 +200% 7,500 30 Nov 2021 Direct F1
transaction URGN Ordinary Shares Sale $31,122 -2,587 -34% $12.03 4,913 30 Nov 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -5,000 -33% $0.000000 10,000 30 Nov 2021 Ordinary Shares 5,000 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
F3 1/3 of the shares underlying the stock options will vest on each of November 30, 2021, October 1, 2022 and October 1, 2023.